GSK3B and cancer: When cancer occurs, the Wnt pathway is activated, triggering the phosphorylation of Dvl, and then, the activity of GSK-3β is inhibited, thereby attenuating β-catenin phosphorylation [29] and ultimately suppressing the degradation of β-catenin and thus promoting its nuclear translocation.